Analyst upgrades typically lead to a positive short-term reaction in the stock market as they reflect a positive change in the company's outlook. Stifel's upgrade from Hold to Buy suggests a strong confidence in Tandem Diabetes Care's future performance, likely leading to increased investor interest and a rise in stock price.